article thumbnail

After Roche breakup, Blueprint Medicines finds Gavreto a new home at Rigel

Fierce Pharma

As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.

Medicine 286
article thumbnail

Europe names hundreds of critical medicines in quest to counter drug shortages

Fierce Pharma

Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S.

Medicine 359
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Kaiser Permanente Unveils Food is Medicine Center of Excellence

MedCity News

Kaiser Permanente’s new Food is Medicine Center of Excellence will “combine clinical services, research, education and community engagement,” according to the organization. The post Kaiser Permanente Unveils Food is Medicine Center of Excellence appeared first on MedCity News.

Food 105
article thumbnail

The growing uses of medicinal cannabis

Pharmaceutical Technology

Demand for medicinal cannabis is increasing globally to treat a range of illnesses and conditions.

Medicine 136
article thumbnail

Teva UK partners Closed Loop on personalised medicine

pharmaphorum

Teva UK has joined forces with techbio company Closed Loop Medicine to develop digital companions for pharma products that could provide personalised medicine

article thumbnail

Mitigating medicines shortages in Europe

European Pharmaceutical Review

While unsolicited and burdensome, medicine shortages are an obstacle faced by the pharmaceutical industry. In 2023, a combination of factors, including increased demand (particularly for critical medicines), economic inflation, as well as international geopolitical unrest, has led to Europe’s supply chain being acutely affected.

Medicine 104
article thumbnail

Europe publishes first list of critical medicines

European Pharmaceutical Review

The European Commission, the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the first Union list of critical medicines. The Union list was put together following a review of 600 active substances taken from six national lists of critical medicines.

Medicine 102